Abstract

Background: Nodule is an inflammatory lesion common in scabies, treating nodular scabies is a challenge. We conducted this study to evaluate the results of treating nodular scabies with Clobetasone butyrate 0.05% in children at the National Dermatology Hospital. Material and methods: Randomized controlled clinical trial study on 100 patients diagnosed with scabies at the age of 2 - 15 years at the National Dermatology Hospital. The study group used Clobetasone butyrate 0.05% with Desloratidine, the control group used Cetaphil Moisturizing with Desloratidine, evaluating the treatment effect after two weeks. Results: The number of nodular lesions in the study group before treatment was 8.72 ± 8.93 and after treatment decreased to 4.2 ± 3.5. In the control group, the number of nodules before treatment was 9.8 ± 9, and after treatment reduced to 6.7 ± 6.5. After two weeks of treatment, the number of nodules decreased with statistical significance in the study group. Treatment response in the study group showed good, average, fair and poor results of 12%, 66%, 22%, 0% respectively; while the control group was 0%, 4%, 46%, 50%; The difference is statistically significant in the two groups. Itching symptom in the study group improved better than the control group. No side effects were recorded in either group. Conclusion: Treatment of nodular scabies with Clobetasone butyrate 0.05% in children reduced the number of lesions, itching symptoms after two weeks and had not recorded any side effects